ANTAGONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Antagonate, and when can generic versions of Antagonate launch?
Antagonate is a drug marketed by Bayer Pharms and is included in one NDA.
The generic ingredient in ANTAGONATE is chlorpheniramine maleate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Antagonate
A generic version of ANTAGONATE was approved as chlorpheniramine maleate by AVANTHI INC on May 13th, 2009.
Summary for ANTAGONATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 81 |
Patent Applications: | 2,749 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANTAGONATE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ANTAGONATE
US Patents and Regulatory Information for ANTAGONATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Pharms | ANTAGONATE | chlorpheniramine maleate | TABLET;ORAL | 083381-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |